Affimed N Vis A Clinical Stage Biopharmaceutical Company Based In Mannheimgermanyfocused On Developing Innovative Immunotherapies For Treating Solid And Hematologic Cancersfounded In 2000 And Publicly Traded On Nasdaq Under The Tickerafmd Affimed Utilizes Its Proprietary Innate Cell Engagericeplatform To Activate The Body S Immune Systemparticularly Natural Killernkcellsto Target And Eliminate Cancer Cells The Company S Product Pipeline Includes Several Promising Therapiesafm13 Targets Cd30 Positive Cancersafm24 Is Designed For Egfr Expressing Solid Tumorsand Afm28 Focuses On Cd123 Positive Acute Myeloid Leukemiaadditionallyafvt 2101Afm32Is A Preclinical Candidate Aimed At Solid Tumorsaffimed Collaborates With Academic Institutions And Biopharmaceutical Partners To Advance Its Clinical Trialswith A Mission To Improve The Lives Of Cancer Patients
